Cytokinetics Statistics
Total Valuation
Cytokinetics has a market cap or net worth of $11.74 billion. The enterprise value is $12.37 billion.
| Market Cap | 11.74B |
| Enterprise Value | 12.37B |
Important Dates
The next estimated earnings date is Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cytokinetics has 135.77 million shares outstanding. The number of shares has increased by 4.46% in one year.
| Current Share Class | 135.77M |
| Shares Outstanding | 135.77M |
| Shares Change (YoY) | +4.46% |
| Shares Change (QoQ) | +2.64% |
| Owned by Insiders (%) | 0.43% |
| Owned by Institutions (%) | 108.85% |
| Float | 135.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 110.97 |
| Forward PS | 82.98 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 116.88 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.21
| Current Ratio | 4.21 |
| Quick Ratio | 4.14 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.60 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -31.54% |
| Return on Invested Capital (ROIC) | -62.88% |
| Return on Capital Employed (ROCE) | -59.60% |
| Weighted Average Cost of Capital (WACC) | 6.54% |
| Revenue Per Employee | $157,229 |
| Profits Per Employee | -$1.23M |
| Employee Count | 673 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +157.11% in the last 52 weeks. The beta is 0.42, so Cytokinetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.42 |
| 52-Week Price Change | +157.11% |
| 50-Day Moving Average | 74.04 |
| 200-Day Moving Average | 65.15 |
| Relative Strength Index (RSI) | 70.79 |
| Average Volume (20 Days) | 2,547,838 |
Short Selling Information
The latest short interest is 14.77 million, so 10.88% of the outstanding shares have been sold short.
| Short Interest | 14.77M |
| Short Previous Month | 15.50M |
| Short % of Shares Out | 10.88% |
| Short % of Float | 10.93% |
| Short Ratio (days to cover) | 8.60 |
Income Statement
In the last 12 months, Cytokinetics had revenue of $105.82 million and -$829.61 million in losses. Loss per share was -$6.84.
| Revenue | 105.82M |
| Gross Profit | -307.63M |
| Operating Income | -640.25M |
| Pretax Income | -829.61M |
| Net Income | -829.61M |
| EBITDA | -629.04M |
| EBIT | -640.25M |
| Loss Per Share | -$6.84 |
Balance Sheet
The company has $818.55 million in cash and $1.44 billion in debt, with a net cash position of -$625.07 million or -$4.60 per share.
| Cash & Cash Equivalents | 818.55M |
| Total Debt | 1.44B |
| Net Cash | -625.07M |
| Net Cash Per Share | -$4.60 |
| Equity (Book Value) | -826.57M |
| Book Value Per Share | -6.65 |
| Working Capital | 640.28M |
Cash Flow
In the last 12 months, operating cash flow was -$523.85 million and capital expenditures -$25.07 million, giving a free cash flow of -$548.92 million.
| Operating Cash Flow | -523.85M |
| Capital Expenditures | -25.07M |
| Depreciation & Amortization | 11.20M |
| Net Borrowing | 316.10M |
| Free Cash Flow | -548.92M |
| FCF Per Share | -$4.04 |
Margins
| Gross Margin | -290.73% |
| Operating Margin | -605.06% |
| Pretax Margin | -784.02% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Cytokinetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.46% |
| Shareholder Yield | -4.46% |
| Earnings Yield | -7.06% |
| FCF Yield | -4.67% |
Analyst Forecast
The average price target for Cytokinetics is $107.90, which is 24.75% higher than the current price. The consensus rating is "Buy".
| Price Target | $107.90 |
| Price Target Difference | 24.75% |
| Analyst Consensus | Buy |
| Analyst Count | 22 |
| Revenue Growth Forecast (3Y) | 114.51% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 25, 2013. It was a reverse split with a ratio of 1:6.
| Last Split Date | Jun 25, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:6 |
Scores
Cytokinetics has an Altman Z-Score of -3.29 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.29 |
| Piotroski F-Score | 3 |